Gm514 Inhibitors
The class of compounds known as UBAP1L inhibitors encompasses a variety of chemical entities designed to modulate the activity of the Ubiquitin-associated protein 1-like (UBAP1L). These compounds are characterized by their ability to specifically interact with UBAP1L, a protein implicated in the intricate ubiquitin-proteasome system responsible for protein turnover and regulation within the cell. The mechanism of action for UBAP1L inhibitors typically involves direct interaction with the protein, which may include binding to its active site, inducing conformational changes that disrupt its function, or hindering its ability to form complexes with other proteins in the ubiquitination cascade. The specificity of these inhibitors is paramount, as it ensures targeted modulation of UBAP1L activity without off-target effects on other proteins.
Chemical compounds within the UBAP1L inhibitors class are diverse in structure, ranging from small molecules to more complex synthetic entities. Their development is underpinned by an intricate understanding of UBAP1L's three-dimensional structure and its role within cellular processes. These inhibitors are engineered to fit precise regions on UBAP1L, ensuring that they engage the protein with high affinity and selectivity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to an accumulation of ubiquitinated proteins and potentially affecting proteins like UBAP1L that are associated with ubiquitin. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective proteasome inhibitor, similar to Bortezomib, that can disrupt the degradation of ubiquitin-tagged proteins, hence indirectly influencing UBAP1L's function or stability. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a reversible proteasome inhibitor that can prevent the degradation of ubiquitin-conjugated proteins and may affect UBAP1L indirectly by altering protein turnover in the cell. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a natural product that irreversibly inhibits the proteasome, which could lead to a buildup of proteins involved in the ubiquitin pathway, including UBAP1L. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
MLN2238, also known as Ixazomib, is a proteasome inhibitor that can affect the degradation of ubiquitinated proteins, hence potentially influencing the cellular concentration and function of UBAP1L. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective inhibitor of the proteasome, which may cause an accumulation of ubiquitin-conjugated proteins, thereby indirectly affecting the function of UBAP1L. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is an inhibitor of the ubiquitin-activating enzyme E1, leading to reduced ubiquitination of proteins. This could indirectly affect UBAP1L by impacting the ubiquitin-proteasome system's ability to tag proteins for degradation. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to inhibit the proteasomal activity, which might lead to altered levels of ubiquitinated proteins and indirectly affect proteins like UBAP1L. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an orally bioavailable proteasome inhibitor, which could impact the turnover of ubiquitinated proteins, thus potentially influencing UBAP1L indirectly. | ||||||